BioSpace News Archive

EDAP TMS SA (Nasdaq: EDAP), the global leader in robotic energy-based therapies, announced today that its Focal One platform has been granted Breakthrough Device designation by the US Food and Drug Administration (FDA) for the treatment of deep infiltrating endometriosis (DIE).

EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) today announced the appointment of Ramiro Ribeiro, M.D., Ph.D. as Chief Medical Officer to succeed Dario Paggiarino, M.D. who has served as EyePoint’s Chief Medical Officer since 2016.

Passage Bio, Inc. (Nasdaq: PASG) today reported financial results for the fourth quarter and year ended December 31, 2023 and provided recent business highlights.

Apollomics Inc., a clinical-stage biopharmaceutical company developing medicines to address difficult-to-treat cancers, announced that Matthew Plunkett, Ph.D., has been appointed as Chief Financial Officer of Apollomics.

YolTech Therapeutics announced the Center for Drug Evaluation of the National Medical Products Administration has officially approved the YOLT-201 investigational new drug application for a Phase I study, marking that the drug candidate has officially entered the registration clinical development stage.

DURECT Corporation, announced that it has entered into a co-marketing and collaboration agreement with Charles River Laboratories for the ALZET® Osmotic Pumps Portfolio and Associated Product Line in the U.S. and Canada.

Antibe Therapeutics Inc. announced that the arbitrator has found in favor of Nuance Pharma in the dispute regarding the license agreement for the commercialization of otenaproxesul in the Greater China region.

Indaptus Therapeutics, Inc, (Nasdaq: INDP), a clinical stage biotechnology company dedicated to pioneering innovative cancer and viral infection treatments, announces positive results from the second cohort of its Phase 1 INDP-D101 trial.

Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, announced the appointment of Mary Tagliaferri, M.D. to the Company’s Board of Directors, effective February 29, 2024.

Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper) today announced results for the fiscal quarter and year ended December 31, 2023, and reported recent corporate developments.